




PHARMACEUTICAL 2022

Foghorn Therapeutics Inc.
Rank 356 of 466





RealRate

PHARMACEUTICAL 2022

Foghorn Therapeutics Inc. Rank 356 of 466



The relative strengths and weaknesses of Foghorn Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foghorn Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Foghorn Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 199% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 64% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	459,562
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	48,692
Liabilities, Non-Current	374,211
Other Assets	60,212
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-586
Other Revenues	1,319
Property and Equipment	0
Research and Development	80,325
Selling, General and Administrative Expense	21,728

Output Variable	Value in 1000 USD
Assets	519,774
Liabilities	422,903
Expenses	102,053
Revenues	1,319
Stockholders Equity	96,871
Net Income	-101,320
Comprehensive Net Income	-101,322
Economic Capital Ratio	14%